GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Endoscopy/Optical assessment of scars after EMR - STAR-LNPCP Trial

Optical assessment of scars after EMR - STAR-LNPCP Trial

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated June 1, 2025

Quick Answer

The STAR-LNPCP trial conducted a multicenter study to assess the reliability of optical assessment as a follow-up method for scars after piecemeal endoscopic mucosal resection (EMR) of large colorectal polyps (≥20 mm). The study aimed to determine whether routine biopsy is still necessary during the 6-month follow-up, especially in community hospital settings where evidence has been limited.


The STAR-LNPCP trial conducted a multicenter study to assess the reliability of optical assessment as a follow-up method for scars after piecemeal endoscopic mucosal resection (EMR) of large colorectal polyps (≥20 mm). The study aimed to determine whether routine biopsy is still necessary during the 6-month follow-up, especially in community hospital settings where evidence has been limited. Traditionally, follow-up included tattoo placement and routine biopsies to detect recurrence, but expert centers have suggested that careful optical assessment may suffice, potentially avoiding unnecessary biopsies.

### Key Details of the STAR-LNPCP Trial:

1. **Study Design**:

  • Post-hoc analysis of the STAR-LNPCP trial.
  • Conducted across 30 Dutch community hospitals between 2019 and 2022.
  • Included 1277 scar assessments after piecemeal EMR.

2. **Scar Identification**:

  • Scar identification was highly successful, achieved in 95% of cases (1215 out of 1277).
  • Tattoo placement did not impact the ability to locate scars.

3. **Routine Biopsy**:

  • Routine biopsies were performed in 86% of cases (1050 out of 1215 scars).
  • Recurrence was detected in 19% of biopsied scars.

4. **Optical Assessment Findings**:

  • Optical diagnosis showed a **negative predictive value (NPV)** of 98%, meaning if the scar appeared normal to the endoscopist, there was a 98% chance that no recurrence was present.
  • Diagnostic accuracy was high at 93%, with a **Cohen's kappa** of 0.78, indicating substantial agreement between optical assessment and histological biopsy results.
  • Positive predictive value was 74%, but false positives were more common when clips had been used during the initial procedure (11% vs. 5%).

5. **Performance of Dedicated Endoscopists**:

  • Dedicated endoscopists performed better than non-specialized endoscopists:
  • Higher scar identification rate (96% vs. 88%).
  • Fewer missed recurrences.

6. **Implications**:

  • The study supports that routine biopsies and tattoo placement can be safely omitted during follow-up when scars are evaluated by well-trained, dedicated endoscopists.
  • Optical assessment alone is highly reliable for ruling out recurrence, simplifying follow-up and reducing unnecessary procedures.

### Conclusion:

The STAR-LNPCP trial demonstrated that optical assessment is a robust and effective method for follow-up of scars after piecemeal EMR of large colorectal polyps. With a high negative predictive value and diagnostic accuracy, routine biopsy may no longer be necessary, particularly when performed by skilled endoscopists. This approach can streamline follow-up in community hospital settings, reduce patient burden, and minimize unnecessary interventions.

Related Q&A

EndoBarrier Improves Diabetes and Weight Loss: Ann Surg | July 2026

Introduction: Endoscopic metabolic therapies have emerged as less invasive alternatives to bariatric surgery for patients with obesity and poorly controlled type 2 diabetes mellitus (T2DM). The EndoBarrier duodenal-jejunal bypass liner (DJBL) is an endoscopically placed...

Immediate Endoscopic Necrosectomy in Necrotizing Pancreatitis: Gastroenterology | July 2026

Introduction: Endoscopic ultrasound (EUS)-guided transmural drainage is the standard minimally invasive treatment for symptomatic necrotizing pancreatitis. However, the optimal timing of direct endoscopic necrosectomy (DEN) following drainage remains uncertain. While the conventional step-up approach reserves...

Endoscopy After Bevacizumab Appears Safe: GIE | July 2026

Introduction: Bevacizumab is widely used in metastatic colorectal cancer (mCRC) because of its survival benefits but is associated with impaired wound healing, gastrointestinal perforation, and bleeding. These concerns often lead clinicians to delay endoscopic procedures...

Colorectal ESD Perforation: Endoscopy | July 2026

Introduction: Endoscopic submucosal dissection (ESD) enables en bloc resection of large colorectal neoplasms with excellent oncological outcomes. However, concerns about perforation have limited its widespread adoption. This large prospective multicenter study evaluated the incidence, risk...

Duodenal Mucosal Resurfacing REMAIN-1 Study: DDW | 2026

Introduction: Obesity has become one of the greatest global health challenges. New incretin-based therapies—including semaglutide, tirzepatide, resmetirom, and SGLT2 inhibitors such as empagliflozin—have transformed the treatment of obesity, diabetes, and MASLD. However, many patients discontinue...

EUS-FNAB for Solid Pancreatic Lesions: GIE | July 2026

Introduction: Endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) is the standard technique for diagnosing solid pancreatic lesions. Traditionally, biopsy specimens are processed for cytology, often requiring on-site cytopathology support. This multicenter prospective study evaluated whether directly placing...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer